TELA Bio Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Cash & Equivalents	46.99	42.02	43.93	74.39	45.3	17.28	11.37
Short-Term Investments	0	0	0	0	9.29	0	0
Cash & Cash Equivalents	46.99	42.02	43.93	74.39	54.59	17.28	11.37
Cash Growth	11.84%	-4.35%	-40.95%	36.29%	215.93%	51.96%	-
Receivables	9.74	6.62	4.23	2.68	2.84	1.3	0.76
Inventory	13.16	11.79	7.66	3.91	4.6	4.35	1.82
Other Current Assets	1.83	2.02	3.23	2.24	2.31	0.33	0.41
Total Current Assets	71.73	62.45	59.06	83.23	64.33	23.25	14.35
Property, Plant & Equipment	3.94	2.91	1.19	0.63	0.68	0.76	1.16
Goodwill and Intangibles	2.12	2.5	2.3	2.61	2.91	3.22	0
Other Long-Term Assets	0.27	0	0	0	0	0	0.02
Total Long-Term Assets	6.32	5.41	3.49	3.23	3.59	3.97	1.19
Total Assets	78.05	67.86	62.54	86.46	67.92	27.23	15.53
Accounts Payable	1.67	1.53	2.41	0.65	3.17	3.42	1.51
Current Debt	0	0	0	0	0	0	0.91
Other Current Liabilities	15.3	10.87	8.16	5.95	3.54	6.14	3.74
Total Current Liabilities	16.97	12.4	10.58	6.61	6.71	9.56	6.15
Long-Term Debt	40.52	39.92	31.49	30.83	30.24	29.73	3.61
Other Long-Term Liabilities	1.69	1.23	0.38	0	0	1.65	2.6
Total Long-Term Liabilities	42.2	41.15	31.87	30.83	30.25	31.38	6.21
Total Liabilities	59.17	53.55	42.45	37.43	36.96	40.94	12.35
Total Debt	40.52	39.92	31.49	30.83	30.24	29.73	4.52
Debt Growth	1.50%	26.75%	2.15%	1.93%	1.72%	558.54%	-
Retained Earnings	-320.89	-274.23	-229.93	-196.65	-167.86	-137.86	-108.17
Comprehensive Income	0.09	0.15	-0.05	-0.07	-0.02	0	0
Shareholders' Equity	18.88	14.31	20.1	49.03	30.96	-137.86	-108.17
Net Cash / Debt	6.48	2.1	12.44	43.57	24.34	-12.46	6.86
Net Cash / Debt Growth	208.08%	-83.09%	-71.45%	78.96%	-	-	-
Net Cash Per Share	0.28	0.13	0.86	3.37	13.78	-42.22	23.48
Working Capital	54.76	50.04	48.48	76.62	57.62	13.7	8.2
Book Value Per Share	0.83	0.88	1.39	3.79	17.53	-467.34	-370.50

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).